A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters (OTW)

A Post-market Clinical Study to Confirm the Performance and Safety of the LeMaitre TufTex Over-the-Wire (OTW) Embolectomy Catheter on Patients Undergoing Surgical Treatment for the Removal of Arterial Emboli and/or Thrombi

A PMCF study to confirm the performance and safety of the LeMaitre® TufTex Over-the-Wire Embolectomy Catheter

Study Overview

• Status: Recruiting
• Conditions: Thrombus; Embolus; Occlusion; Vessel
• Intervention / Treatment: Device: TufTex Over-the-Wire Embolectomy Catheter

Detailed Description

This clinical investigation is a prospective, single-arm, multicenter, post-market study to proactively collect clinical data on the LeMaitre® TufTex Over-the-Wire (OTW) Embolectomy Catheters and to confirm its performance in removing arterial emboli and/or thrombi, to identify and analyze emergent risks on the basis of factual evidence, and to ensure the continued acceptability of the benefit/risk ratio. The intended purpose of the device in this post market clinical study is identical to the indication of use of the device.

The TufTex OTW post-market study is initiated by the Sponsor and manufacturer of the device, LeMaitre Vascular, Inc.

The investigation will take place in 4 sites, most likely in 3 different countries. A total number of 112 subjects is anticipated to be enrolled, who are intended to undergo surgical treatment for the removal of a emboli and/or thrombi. The anticipated enrollment period is 48 months, and the participation per subject is 1 month. The total study duration is expected to be 56 months (4 months start-up, 48 months of recruitment, 1 month of follow-up, 3 months of closure.

• Study Type: Interventional
• Enrollment (Estimated): 112
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Andrew Hodgkinson; Phone Number: 781-425-1664; Email: ahodgkinson@lemaitre.com
• Study Contact Backup: Name: Brian Orrick; Phone Number: 781-425-1685; Email: borrick@lemaitre.com

Study Locations

• Germany
  • Brandenburg, Germany
    • Recruiting
    • Andrej Udelnow
    • Contact: Andrej Udelnow; Email: a.udelnow@klinikum-brandenburg.de
  • Dresden, Germany
    • Not yet recruiting
    • University Hospital Carl Gustav Carus TU Dresden
    • Contact: Sandra Korn; Email: sandra.korn@uniklinikum-dresden.de
• Switzerland
  • Lugano, Switzerland
    • Recruiting
    • Ospedale Regionale di Lugano - sede Civico
    • Contact: Giorgio Prouse, MD; Email: Giorgio.Prouse@eoc.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male and female subject, ≥ 18 years of age at time of enrollment.
2. Subject who is scheduled to undergo surgical treatment for the removal of an emboli or thrombi during an embolectomy and/or thrombectomy procedure, where one of the LeMaitre® Embolectomy Catheter will be used.
3. Subject signed an Informed Consent for participation.
4. Subject diagnosed with a embolus/thrombus.
5. Subjects for whom thrombolytic therapy had failed or was contraindicated.

Exclusion Criteria:

1. Co-morbidity that in the discretion of the investigator might confound the results.
2. Subjects who are unable to read or write.
3. Pregnant or lactating women at time of enrollment
4. Subjects who are immune compromised

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: LeMaitre TufTex Over-the-Wire Embolectomy Catheter; The LeMaitre Over the Wire Embolectomy Catherer is indicated for use in the removal of emboli and thrombi during embolectomy and/or thrombectomy. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.	Device: TufTex Over-the-Wire Embolectomy Catheter; The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance objective is the technical success being <30% residual stenosis	The primary performance objective of the study is the technical success as defined as <30% residual stenosis of the target vessel as evaluated on the completion digital subtraction angiography (DSA).	1 month post index procedure
Safety objective is defined as acceptable safety outcomes during the procedure and at follow-up	The primary safety objective is defined as acceptable safety outcomes (e.g. (Serious) Device and/or Procedure Related Events) during the procedure and 1 Month post index procedure.	1 month post index procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1.Clinical success	Clinical success is target vessel dependent and defined as; 1. the absence of target vessel limb amputation post-intervention in case of limb cloths, and 2. successful dialysis sessions performed post-intervention in case of dialysis shunt revascularization	1 month post index procedure
2. Revision rate	Revision rate is defined as the number of patients with target vessel reintervention	1 month post index procedure
3. Primary assisted patency	Primary assisted patency is defined as target vessel patency; the target vessel is patent but there may have been some intervention required to maintain that patency.	1 month post index procedure
4. Secondary patency	Secondary patency is defined as the target vessel patency including target vessel that have been occluded and there has been an intervention to restore patency	1 month post index procedure

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory endpoints	Number of LeMaitre® TufTex OTW Embolectomy Catheters used per intervention	1 month post index procedure

Collaborators and Investigators

• Sponsor: LeMaitre Vascular
• Collaborators: Avania
• Investigators: Principal Investigator: Giorgio Prouse, MD, Ospedale Regionale di Lugano - sede Civico; Principal Investigator: Andrej Udelnow, MD, University of Brandenburg; Principal Investigator: Sandra Korn, MD, University Hospital Carl Gustav Carus

Study record dates

Study Major Dates

• Study Start (Actual): January 11, 2023
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: May 10, 2022
• First Submitted That Met QC Criteria: May 18, 2022
• First Posted (Actual): May 23, 2022

Study Record Updates

• Last Update Posted (Actual): September 26, 2023
• Last Update Submitted That Met QC Criteria: September 22, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Embolism and Thrombosis; Embolism; Thrombosis
• Other Study ID Numbers: EC-16-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes